Glycosylation Regulates IgE Production and Stability in Vivo

Avishek Roy,Steve Meregini,Zhenglan Chen,Evan Nair-Gill,Sara Ludwig,Jamie Russell,Jiexia Quan,Sara Hildebrand,Eva Moresco,Tao Yue,Bruce Beutler,Jeffrey SoRelle

DOI: https://doi.org/10.1016/j.jaci.2022.12.684

2023-01-01

Abstract:IgE is a heavily glycosylated immunoglobulin and recent studies have indicated an oligomannose glylcan is essential for Fcer1a binding and sialyation drives IgE pathogenicity. We performed a forward genetic screen of allergic response on N-ethyl-N-nitrosourea (ENU) mutagenized mice. A candidate mouse phenotype, benadryl, was validated with CRISPR knock-in of the mutant allele/ creation of a flox allele, and immunologic studies (passive/ active anaphylaxis, mast cell analysis, conditional knockout in T, B and dendritic cells, antibody production in vivo and in vitro, using IgE-Venus, IgE-KO, and IL-4 GFP mice) were performed to determine the causative mechanism. Low total and papain-specific IgE was confirmed in the CRISPR KI mice, which were also resistant to active anaphylaxis. We ruled out the possibility of a mast cell defect by in vitro activation assays and by finding no difference in the response to passive sensitization anaphylaxis. Conditional knockout, in vitro cell culture, and in vivo cellular staining pinpointed the low IgE phenotype to B cells. IgE from Mpi deficient mice was hypoglycosylated, but produced and secreted from B cells in culture. When de-glycosylated IgE was injected to IgE KO mice, it was cleared 10 fold faster than native IgE. We conclude that glycosylation is important not just for IgE function, but also stability in vivo. Hypoglycosylated IgE is produced, but cleared faster in Mpi deficient mice, which makes them resistant to active anaphylaxis. While systemic loss of glycosylation has undesireable effects, targeting glycosylation on IgE molecules may represent an interesting therapeutic opportunity.